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Abstract Human brain hexokinase type I, expressed in 
Escherichia coli, has been crystallized from polyethylene glycol 
8000 in the presence of inorganic phosphate. The crystals are 
hexagonal needles of diameter 0.25 ram, diffracting to a 
resolution of 3.5 A on a rotating-anode/area-detector system. 
The crystals belong to the space groul~ P3121/P3221 with cell 
dimensions a = b = 171.5 A and c = 99.4 A. The specific volume of 
the crystal is 4.2 ~,3/Da, suggesting an asymmetric unit with a 
single 100 kDa molecule and a solvent content of 71% by volume 
or two molecules of hexokinase with a solvent content of 41%. 
The complex of hexokinase with glucose crystallizes under 
similar conditions, giving crystals of the same morphology. 
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Hexokinase I (ATP: o-hexose 6-phosphotransferase, EC 
2.7.1.1) is one of four mammalian hexokinase isozymes. It is 
the pacemaker of glycolysis in brain and red blood cells [1,2]. 
In fact, the human brain uses approximately 50% of the total 
chemical energy expended by the human body, a demand met 
almost entirely by the activity of hexokinase type I in the 
brain [2]. 
Type I and II isozymes have a number of features which 
distinguish them from other mammalian hexokinases and 
from eukaryotic glucokinases, such as yeast hexokinase. 
Hexokinases type I and type II bind to the outer membrane 
of mitochondria [3] and are inhibited strongly by their reac- 
tion product glucose-6-phosphate [1,4-6]. Hexokinase type I 
differs from hexokinase type II in that the product inhibition 
can be reversed by physiological levels of inorganic phosphate 
[1,4,5]. These properties of hexokinase type I may make it a 
critical regulator of glycolysis in brain tissue and erythrocytes 
[1,2,4,7]. 
Human brain hexokinase is a 100 kDa enzyme, consisting 
of two highly homologous (50% identity) sequence domains. 
Each sequence domain in turn is homologous (30% identity) 
to yeast hexokinase and human glucokinase (hexokinase type 
IV). Presumably, human brain hexokinase volved from a 50 
kDa yeast-like nzyme by gene duplication and fusion [8,9]. 
Hexokinase type I, lacking the N-terminal sequence domain 
(mini-hexokinase), has the same kinetic properties toward glu- 
cose, ATP, and glucose-6-phosphate s intact brain hexoki- 
nase type I [10]. Mini-hexokinase, however, exhibits inhibition 
by glucose-6-phosphate, which cannot be reversed by phos- 
phate [11,12]. The N-terminal sequence domain is inactive, 
generally being regarded as a modulator of activity [10]. Glu- 
cose-6-phosphate binds near or at the ATP site on the C- 
terminal sequence domain [1,12], rather than, as originally 
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suggested [2,13], to an allosteric site on the N-terminal se- 
quence domain. On the basis of kinetics [1], the binding site 
for glucose-6-phosphate is different from that of glucose. 
The structure of yeast hexokinase is known [14-16], but the 
Protein Data Bank [17] has only two relevant entries with 
sequences deduced from 2.1 A and 3.5 A electron density 
maps. The binding of glucose to the active site causes a 12 ° 
rotation of one of the structural domains of the yeast enzyme, 
transforming it into an active form [18]. Though the structure 
of yeast hexokinase has been used for modeling the glucose 
and ATP binding sites of brain hexokinase ([19]; Zeng, C., 
Aleshin, A.E., Harrison, R.W., Chen, G. and Fromm, H.J., 
personal communication), the yeast enzyme is of little help in 
understanding the regulatory properties of hexokinase type I. 
Furthermore, yeast hexokinase and hexokinase type I exhibit 
significant differences in their interaction with glucose-6-phos- 
phate [1]. 
Reported here are the crystallization conditions and prelim- 
inary X-ray diffraction investigation of human brain hexoki- 
nase type I. The cloned enzyme was produced in Escherichia 
coli strain BL21 (DE3) and purified as described earlier 
[12,20]. The initial conditions for crystallization were discov- 
ered by the method of hanging drops, using a sparse screening 
matrix [21]. Crystals grew at room temperature under the 
following conditions: 5 gl of the protein solution of concen- 
tration 20 mg/ml in 20-40 mM sodium phosphate buffer (pH 
6.5) was mixed with the same amount of a precipitant solution 
containing 3-5% (w/v) polyethylene glycol 8000 (Sigma) and 
0.1 M sodium cacodylate buffer at pH 6.5. The drops were 
equilibrated against 0.7 ml of the precipitant solution. Long 
hexagonal needles of diameter 0.1-0.3 mm appeared within 
1 week. Crystals of similar morphology also appeared under 
the same conditions, but with 10 mM glucose present in the 
protein solution. Taking into account hat the constants of 
dissociation for phosphate and glucose are 22 gM [22] and 
60 laM [12], respectively, we suggest that the first crystal form 
contains bound phosphate and the second one both ligands. 
The addition of glucose did not change the morphology of 
crystals, suggesting that hexokinase type I in both complexes 
may have similar conformations (Fig. 1). 
We collected ata from crystals of brain hexokinase type I, 
complexed with phosphate, on a Siemens area detector 
mounted on an X-ray generator with a Cu rotating anode. 
We observed diffraction to a resolution of 3.5 ,~. Due to 
problems of decay, however, we limited data collection to 
3.8 ./~ resolution. The data set contains 33 375 observations, 
15 449 of which are unique reflections (91% of data expected 
to 3.8 ,~). Data reduction with XENGEN [23] gave R~.g equal 
to 0.07. 
The crystals of hexokinase type I belong to space group 
P3221/P3121. The unit cell dimensions are a=b=171.5 A
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Fig. 1. Photograph of human brain hexokinase crystal. The dia- 
meter of the crystal is 0.25 mm. 
and c = 99.4 A. If one protein molecule lies in the asymmetric 
unit, the Vm is 4.2 ,A,3/Da and the fractional volume occupied 
by the solvent is 71%. These values are almost wo-fold great- 
er than the average value observed in other protein crystals 
[24], which raises the possibility of two molecules of hexoki- 
nase type I in the asymmetric unit with a solvent content of 
41%. Protein crystals with trigonal cells, however, generally 
have a high content of solvent [24]. The susceptibility of the 
crystal to damage by X-rays and its modest diffraction limit 
are properties consistent with a loosely packed asymmetric 
unit, containing a single enzyme molecule and a high solvent 
content. 
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